Unlock the potential of genomic data
The information within the human genome can help us diagnose rare diseases, identify individuals at risk of developing certain conditions and create effective treatment regimens. But today’s genomic data sets often come with limitations for researchers. They’re noisy, not representative, and lack information on the patient journey, limiting their value.
Optum Life Sciences combines the rich depth of genomic sequencing data with our world-class clinical and claims assets to offer researchers a new frontier in their search for life-changing treatments, vaccines and cures.
Accelerate time to market for targeted therapies
Our research-ready, de-identified clinicogenomics data sets link genomic and other -omic data with the longitudinal health record. This allows for:
- Genotypic and phenotypic research across all stages of therapy development and use in the real world
- Comparison of clinical trial data to real-world data (RWD)
- Development of companion diagnostics
- Understanding the genetic testing landscape
With these real-world data, your teams can spend less time on unproductive research and development, and accelerate the time to market for innovative, targeted therapies.
Key benefits
Clinicogenomics data sets should reflect real-life populations. Ours are built to be representative and depict real clinical care.
High-quality RWD foundation
More than 115 million lives of de-identified clinical data allow for more detailed patient journeys from the start.
Data for all therapeutic areas
Beyond our 117,000 individual oncology patients linked with genomic data, our data spans thousands of conditions, including rare diseases.
Real-world populations reflected
For some therapeutic areas, you can design cohorts that are 100% non-Caucasian to analyze specific demographic trends.
Full patient journeys uncovered
Because tumor biology changes over time, our oncology data include sequential sequencing for over 15% of individuals.
Raw sequencing files
Our genomic data comes from raw sequencing files, rather than PDFs or other EMR-based reports.
Research across product lifecycles
From biomarker discovery, to market access, to creating external control arms, our diversified data sets help answer a variety of questions.
Related healthcare insights
Article
Understand how routine clinical practice impacts information captured in real-world data (RWD).
On-demand webinar
Hear from experts in this Endpoints News webinar on the increasing importance of clinicogenomic data, including diverse phenotypic and genotypic profiles.
Video
Optum Life Sciences leaders break down common missteps when using RWD and how to create practical strategies to overcome them. Watch the video from STAT Summit.
Product information and resources
-
Learn more
PDF
Fact sheet
Cardiology and metabolic conditions
Optum can focus a customized cohort on individuals who are diverse with unique combinations of comorbid profiles.
-
Learn more
PDF
Fact sheet
Oncology
Enable precision medicine, reveal the patient journey both before and after diagnosis, and help uncover new information about cancer types.
-
Learn more
PDF
Fact sheet
Autoimmune and inflammatory conditions
Explore the clinical and genomic pillars that reveal which patient populations should receive targeted treatments.